Discounted Cash Flow (DCF) Analysis Unlevered

DiaMedica Therapeutics Inc. (DMAC)

$1.24

0.00 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.24 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.24
Beta 2.041
Diluted Shares Outstanding 15.68
Cost of Debt
Tax Rate -0.21
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 13.438
Total Debt 0.05
Total Equity 19.44
Total Capital 19.50
Debt Weighting 0.27
Equity Weighting 99.73
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%-1.41%-0.29%-0.22%-0.21%-0.43%-0.43%-0.43%-0.43%-0.43%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.02-0.05-0-0.05-0.02-----
UFCF ----------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -4.66
Equity Value -
Shares Outstanding 15.68
Equity Value Per Share -